2C-B

The onset announces itself through the body before the mind. Thirty to sixty minutes after swallowing a dose, a peculiar warmth builds in the stomach -- not quite nausea, not quite excitement, but something between the two. Many users describe a queasy, buzzing restlessness in the gut and muscles. The nausea can range from barely noticeable to genuinely unpleasant (some people vomit during come-up; community advice recommends eating lightly beforehand and having ginger on hand). As this develops, colors begin to saturate, edges shimmer, and there is a subtle sense that reality has been turned up half a notch.

Then the peak arrives and 2C-B's signature visuals reveal themselves. They are vivid -- more colorful, more neon-bright, more "HD" than most psychedelics. Surfaces ripple with geometric overlays: grids, hexagons, flowing organic lattices that hover over the visual field while leaving objects underneath recognizable. Colors shift into hues that don't exist in sober perception. Light sources throw spectacular halos and prismatic tracers, and everything has a crystalline, almost digital clarity that users contrast with the softer visuals of psilocybin or the analytical morphing of LSD. On Reddit, the word that comes up most is "liquid" -- the visual field looks gently submerged in luminous, flowing color.

The cognitive headspace is where 2C-B earns its reputation as the "fun" psychedelic. At common doses (15--22 mg), the mind stays remarkably clear. You can hold conversations, navigate a festival, and generally function in ways impossible on equivalent doses of LSD or psilocybin. There is rarely the existential confrontation or ego dissolution of classical psychedelics. Instead, a warm, glowing sociability -- not the jaw-clenching rush of MDMA, but a gentler openness. Touch feels extraordinary. Music sounds three-dimensional. The emotional tone is wonder, playfulness, and sensory delight rather than philosophical excavation.

The body is mildly stimulated -- a subtle electricity that encourages movement and makes dancing feel natural. There is often pronounced enhancement of physical sensation, including sexual arousal, which Shulgin noted as one of 2C-B's distinctive qualities. The come-up nausea typically resolves once the peak is established.

At higher doses (25 mg+), the character shifts. Visuals become overwhelming, body load returns with force, and cognitive clarity gives way to confusion. The difference between a beautiful trip at 20 mg and a challenging one at 30 mg is not incremental -- it is dramatic.

The comedown is one of 2C-B's most praised qualities. Beginning around three to four hours in, the visuals dim, the warmth softens, and there is a gentle return to baseline over one to two hours. Unlike MDMA, there is no serotonin crash. Unlike LSD, you are not still awake at 3 AM. Most users sleep well and wake without hangover -- a major part of 2C-B's appeal for people who want a complete psychedelic experience that fits within an evening.

Mechanism of Action

2C-B's psychedelic effects are driven by agonism at serotonin 5-HT2A receptors -- the same target as LSD, psilocybin, and mescaline. Binding to 5-HT2A on cortical pyramidal neurons disrupts thalamocortical gating, producing visual distortion, novel pattern perception, and altered self-referential processing .

Early studies created confusion by classifying 2C-B as a low-efficacy partial agonist or even antagonist at 5-HT2A. More recent work has resolved this: 2C-B is a potent partial agonist with an EC50 of ~1.2 nM and near-full efficacy (101%) at 5-HT2A, placing it firmly among classical psychedelics .

Multi-Receptor Profile

What gives 2C-B its distinctive character -- more body-aware than psilocybin, less cognitively demanding than LSD -- is engagement across multiple receptor systems:

• 5-HT2C agonism (EC50 ~0.63 nM, 98% efficacy) -- Mood modulation; may explain 2C-B's anxiolytic quality at lower doses
• 5-HT2B agonism (EC50 ~13 nM) -- Relevant to cardiovascular effects; chronic activation risks valvulopathy, but only with sustained repeated dosing
• Alpha-adrenergic activity -- Drives the stimulant component: elevated heart rate, blood pressure, and the energizing body feel
• Dopamine D1/D4 agonism -- May contribute to 2C-B's rewarding, pleasure-tinged character

Critically, 2C-B does not significantly inhibit monoamine transporters (SERT, NET, DAT) the way MDMA does. It does not cause the massive serotonin dump that drives MDMA's neurotoxicity risk -- a key pharmacological distinction .

Dose-Response Curve

2C-B has an unusually steep dose-response relationship:

• 10--12 mg: Sensory enhancement, empathogenic warmth, minimal visuals
• 15--20 mg: Clear psychedelic visuals, moderate cognitive alteration
• 20--30 mg: Full psychedelic experience, intense visuals, possible ego softening
• >30 mg: Potentially overwhelming; adverse reaction threshold rises sharply

A 5 mg difference can shift the entire character of the experience .

Pharmacokinetics

Oral onset is 45--75 minutes, peak at 60--90 minutes, total duration 4--6 hours. The slow onset is a well-documented source of impatient redosing -- people take a second dose thinking the first failed, then face combined effects. Insufflated onset is 5--15 minutes but produces severe nasal pain universally described as among the worst of any snorted substance. Metabolism likely proceeds via hepatic O-demethylation, though human pathways remain incompletely characterized .

References

Nichols DE. Psychedelics. Pharmacol Rev. 2016;68(2):264-355. In vitro receptor binding and functional assay data compiled from multiple studies. Rickli A et al. Receptor interaction profiles of novel psychoactive tryptamines. Eur Neuropsychopharmacol. 2016;26(8):1327-1337. Papaseit E et al. Acute Pharmacological Effects of 2C-B in Humans. Front Pharmacol. 2018;9:206. Shulgin A, Shulgin A. PiHKAL: A Chemical Love Story. Transform Press. 1991. de Boer D, Bosman I. The 2C-series of phenethylamine designer drugs. Pharm World Sci. 2004;26(2):110-113.

Shulgin's Synthesis (1974)

2C-B was first synthesized by Alexander Shulgin in 1974 as part of his systematic exploration of how substituents at the 4-position of the 2,5-dimethoxyphenethylamine scaffold influenced psychoactive properties. The "2C" designation refers to the two-carbon chain connecting the phenyl ring to the amine group. Shulgin documented 2C-B ascompound #20 in PiHKAL (1991), providing synthesis procedures and vivid first-person descriptions of its effects .

Therapeutic Use (1970s--1990s)

Before scheduling, a small number of psychotherapists used 2C-B in psycholytic sessions (low-dose psychedelic-assisted talk therapy) at doses of 15--30 mg, reporting that it created a warm empathetic bond, helped patients access suppressed emotions, and had desirable therapeutic properties: short duration, gentle side effects, and manageable intensity . Alexander and Ann Shulgin personally used 2C-B to treat over 200 individuals for anxiety, depression, PTSD, and nightmares. Similar use occurred in Germany, the Netherlands, and Switzerland .

Street Market Emergence

After the DEA emergency-scheduled MDMA in July 1985, 2C-B appeared in recreational markets as a legal substitute under street names including Nexus, Erox, Performax, Bromo, Venus, and Spectrum. It was commercially manufactured by small labs, particularly in the Netherlands, and found a niche in the rave scene .

Scheduling (1995--2001)

The DEA placed 2C-B into Schedule I on June 5, 1995, making it the first 2C compound federally scheduled. It was added to the UN Convention on Psychotropic Substances as Schedule II on March 20, 2001 .

Current Status

2C-B remains the most widely used 2C-x compound globally. European seizures rose from 569 incidents in 2022 to 944 in 2023. A 2023 clinical trial comparing 2C-B to psilocybin marked a step toward formal scientific study of a compound long ignored by institutional research .

References

Shulgin A, Shulgin A. PiHKAL: A Chemical Love Story. Transform Press. 1991. Psychedelics.com. 2C-B: Understanding the "Love Child" of Alexander and Ann Shulgin. Passie T. Lower-dose psycholytic therapy. Front Psychiatry. 2022;13:1020505. de Boer D, Bosman I. The 2C-series. Pharm World Sci. 2004;26(2):110-113. UNODC. World Drug Report. Multiple annual editions. Mallaroni P et al. 2C-B vs. Psilocybin. Clin Pharmacol Ther. 2023;114(2):423-430.